Skip to main content

Table 3 Nutritional parameters; safety set

From: Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients

  Dose-titration phase (n= 39) Parallel-group phase
Lanthanum carbonate (n= 10) Placebo (n= 11)
Weight, kg    
  Start of dose-titration phase 76.2 (14.1)
  Start of parallel-group phase 74.9 (13.5)a 73.2 (16.0) 74.1 (12.0)
  End of parallel-group phase 73.2 (17.0) 73.4 (13.6)b
Total serum protein, g/dl    
  Start of dose-titration phase 6.9 (0.8) 6.7 (1.0) 6.9 (0.7)
  Start of parallel-group phase 6.8 (0.7)c 6.6 (0.9) 6.9 (0.4)
  End of parallel-group phase 6.9 (0.7) 6.7 (0.7)d
Serum albumin, g/dl    
  Start of dose-titration phase 3.8 (0.4) 3.7 (0.4) 4.0 (0.3)
  Start of parallel-group phase 3.7 (0.3)c 3.6 (0.4) 3.9 (0.3)
  End of parallel-group phase 3.7 (0.4) 3.6 (0.4)e
  1. Data are presented as mean (standard deviation).
  2. a n = 25; b n = 9; c n = 31; d n = 7; e n = 8.